Navigation Links
DOVER Silicone Elastomer-Coated Latex Foley Catheters 2-Way (Pediatric)

ProductsDOVER Silicone Elastomer-Coated Latex Foley Catheters 2-Way (Pediatric)
Company Kendall Company
Item DOVER Silicone Elastomer-Coated Latex Foley Catheters 2-Way (Pediatric)
Features 
  • Large eyes holes and drainage lumen facilitates urine flow.
  • Thick funnel helps prevent collapse when irrigating.
  • Reinforced tip protects catheter from stylet puncture.
  • Strong symmetric balloons enhances confidence in catheter reliability.
Description Silicone Elastomer-Coated Latex Foley Catheters 2-Way (Pediatric)
Info Kendall Company
Customer Service: (800) 962-9888
Web site: http://www.kendallhq.com

Related medicine products :

1. DOVER 100% Silicone Foley Catheters 3-Way
2. DOVER 100% Silicone Foley Catheters 2-Way (Pediatric)
3. DOVER 100% Silicone Foley Catheters 2-Way
4. DOVER Silicone Elastomer-Coated Latex Foley Catheters 3-Way
5. DOVER Silicone Elastomer-Coated Latex Foley Catheters 2-Way
6. DOVER ULTRAMER Foley Catheter
7. DOVER Silver Foley Catheter 3-way
8. DOVER 100% Silicone Foley Catheter Kits 2-Way
9. DOVER Silver Foley Catheter 2-way
10. DOVER Red Rubber Robinson Catheters (Latex)
11. DOVER ROB-NEL Catheters (100% Latex-Free)
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18UNC awarded 246 2 million renewal grant by NIH Rare Diseases Research Network 10336 1UNC awarded 246 2 million renewal grant by NIH Rare Diseases Research Network 10336 2 Tired Doctors More Prone to Errors 59371 1 Tired Doctors More Prone to Errors 59371 2 Tired Doctors More Prone to Errors 59371 3Discover Red Mangos New Seasonal Flavor 3A Pumpkin Spice 59366 1Discover Red Mangos New Seasonal Flavor 3A Pumpkin Spice 59366 2